Diagnostics Stocks and Companies in India

The largest Diagnostics stocks in India by market value are Dr Lal Pathlabs (₹33,020 crore), Vijaya Diagnostic Centre (₹14,805 crore) and Metropolis Healthcare (₹12,059 crore), at prices of 4 Nov 2026.

• Dr Lal Pathlabs: ₹1,906.40 | market value ₹33,020 crore | P/E 54.5
• Vijaya Diagnostic Centre: ₹1,445.70 | market value ₹14,805 crore | P/E 72.7
• Metropolis Healthcare: ₹581.25 | market value ₹12,059 crore | P/E 57.9
• Thyrocare Technologies: ₹495.50 | market value ₹7,887 crore | P/E 45.1
• Vimta Labs: ₹497.85 | market value ₹2,226 crore | P/E 27.3
• Suraksha Diagnostic: ₹333.05 | market value ₹1,735 crore | P/E 48.4
• Krsnaa Diagnostics: ₹483.05 | market value ₹1,567 crore | P/E 16.1
• 3B Blackbio DX: ₹1,331.50 | market value ₹1,143 crore | P/E 20.6
• One Global Service Provider: ₹439.70 | market value ₹860 crore | P/E 11.6

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 4 Nov 2026; the score list below uses the weekly figures.

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 30 Oct 2026.

All 9 listed Indian Diagnostics companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Diagnostics index; NSE publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. Every figure is equal-weighted across those companies and carries its own as-of date.

1. Dr Lal Pathlabs Ltd₹33,000 cr
2. Vijaya Diagnostic Centre Ltd₹14,800 cr
3. Metropolis Healthcare Ltd₹11,300 cr
4. Thyrocare Technologies Ltd₹7,260 cr
5. Vimta Labs Ltd₹2,170 cr
6. Suraksha Diagnostic Ltd₹1,650 cr
7. Krsnaa Diagnostics Ltd₹1,630 cr
8. 3B Blackbio DX Ltd₹1,110 cr
9. One Global Service Provider Ltd₹858 cr

9 Diagnostics companies in the Diagnostics industry group have a page on Sector Alpha, by market value as of 30 October 2026, and all 9 are listed below, largest first. The largest is Dr Lal Pathlabs (₹33,020 crore) and the smallest with a market value is One Global Service Provider.

Download all 9 Diagnostics companies (CSV)

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 70% ahead of NIFTY 500. Earnings across its companies grew 19% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 23 weeks running.

Price and the fundamentals both up. 3 of 9 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high). 1 is 20% or more behind over a year while earnings grew 20% or more.

Ahead of NIFTY 500 on the three-month view for 23 weeks running; 4 of the 9 companies in the industry index above their 200-day average (3 fewer than four weeks earlier); 3 of those 9 pass the momentum test (1 fewer than four weeks earlier); earnings rising at 6 of the 9 that report earnings.

Participation is shrinking, 4 → 3 of 9 over four weeks, after being ahead of NIFTY 500. Price-only fade, 6 of 9 members have higher trailing twelve-month earnings than a year ago, so the fade is in the price, not in the earnings.

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 9 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Diagnostics has done better than the NIFTY 500 by 16.7% over the last 52 weeks. Over 13 weeks the gap is a lead of 4.5%. Vijaya Diagnostic Centre Ltd is the strongest against the sector itself at +18.1%.

Diagnostics has done better than the NIFTY 500 by 16.7% over 52 weeks and by 4.5% over 13 weeks. 3 of 9 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 4 of the 7 with a long enough price history are ahead of the industry itself.

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

One Global Service Provider Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 80.6% evidence confidence.

Krsnaa Diagnostics Ltd scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

Vijaya Diagnostic Centre Ltd has the strongest one-year price move in Diagnostics at +46.2%. It also leads on relative strength against the NIFTY, at +26.8%. 6 of 9 companies we track are ahead of the index on that measure. Every line covers 313 weekly closes through 30 October 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Diagnostics itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

Strongest against NIFTY 500

Strongest against the sector itself

The whole curve shows several distinct phases: initial weakness, a large run into 2021, a reversal into 2023, and recovery followed by another breakout. The restated quarterly price index moved from 95.7 in December 2016 to 294.7 in December 2021, fell to 138.2 in March 2023, recovered to 264.6 in December 2024, pulled back to 229.2 in March 2026, and rose to 336.8 in September before easing to 323.7 in October. In the week of 5 October 2026, 85.7% of 7 Diagnostics companies were beating the Nifty 500, against 62.5% on 25 May 2026.

Diagnostics is one of the Top 25 sectors in our latest review.

From our industry review of 10 October 2026.

Wider networks, more patients and more specialised tests are supporting growth across several leading companies. Industry-wide debt reduction, compulsory testing rules and broad price increases are not established by this evidence.

From our industry review of 10 October 2026.

7 of 9 Diagnostics companies held a results call for April to June 2026. Krsnaa Diagnostics guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained.

From the results calls for April to June 2026.

Big funds, foreign and Indian, raised their stake by 1.2 points over the last two quarters. Founders and promoters cut theirs by 1.1 points.

• Spending on new plants and equipment was ₹1,441 crore in the last 12 months, 46% more than a year before.
• Projects still being built grew 122% in a year.

Big funds = foreign and Indian institutions, change in their share of ownership across 10 Diagnostics companies, in percentage points.

Ownership and spending as of 10 October 2026.

The next things that show whether the Diagnostics story is on course. First: July to September 2026 results: test whether patient growth persists beyond seasonal illnesses and whether margins absorb expansion costs.

• Krsnaa's promised Q2 Rajasthan revenue ramp, retail-business profitability and Karnataka collections.
• Vijaya's accreditation, hub rollout and higher capital-spending plan.
• Metropolis's specialty cross-sales, Core integration and network productivity.
• Dr Lal's volume and test-mix performance as the government-scheme pricing benefit fades.

What would change the story

The next reported sector quarter showing lower profit than the same quarter a year earlier because revenue growth has stopped would break this revenue-led expansion call.

From our industry review of 10 October 2026.

Dr Lal Pathlabs Ltd has the highest Revenue among the 9 Diagnostics companies compared here, at ₹2,892 crore. Metropolis Healthcare Ltd is next at ₹1,710 crore. One Global Service Provider Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd is the largest at ₹2,892 crore, 69.1% ahead of Metropolis Healthcare Ltd. One Global Service Provider Ltd's growth is capped at 100% on the scoring scale; the full change over the last 12 months is 163.1% from a ₹513 crore base, with 19 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

What this means: Dr Lal Pathlabs Ltd is the size to compare against; One Global Service Provider Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below One Global Service Provider Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

Vijaya Diagnostic Centre Ltd has the highest OPM among the 9 Diagnostics companies compared here, at 44%. Suraksha Diagnostic Ltd is next at 35%. One Global Service Provider Ltd has the highest Margin change at +4 percentage points, so level and change sit with different companies. 9 of 9 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Vijaya Diagnostic Centre Ltd leads opm at 44%; One Global Service Provider Ltd leads margin change at +4 percentage points.

What this means: Vijaya Diagnostic Centre Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Dr Lal Pathlabs Ltd has the highest Net profit among the 9 Diagnostics companies compared here, at ₹545 crore. Metropolis Healthcare Ltd is next at ₹203 crore. One Global Service Provider Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd earns the most, ₹545 crore of profit over the last 12 months, 168.5% above Metropolis Healthcare Ltd. One Global Service Provider Ltd shows at least 100% on the scoring scale (184.6% in full) growth from a profit base of ₹74 crore. A fast rate from a small base matters less than a large profit that keeps coming.

What this means: Dr Lal Pathlabs Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

One Global Service Provider Ltd has the highest ROCE among the 9 Diagnostics companies compared here, at 87%. Thyrocare Technologies Ltd is next at 35.4%. The same company also has the highest ROCE change, at +9.2 percentage points. 9 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: One Global Service Provider Ltd leads ROCE at 87%, 51.6 percentage points above Thyrocare Technologies Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

What this means: One Global Service Provider Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

Withheld from this chart: 3B Blackbio DX Ltd (3BBLACKBIO): its two data sources disagree by up to 41% on reported income across 15 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

One Global Service Provider Ltd has the lowest PEG among the 9 Diagnostics companies compared here, at 0.45×. Krsnaa Diagnostics Ltd is next at 0.57×. The same company also has the lowest P/E, at 11.6×. 8 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: One Global Service Provider Ltd has the lowest comparable PEG at 0.45×, 21.1% below Krsnaa Diagnostics Ltd. That would need today's multiple, the company's own history and steady growth to agree.

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Diagnostics companies show up on 4 of our India lists. The most are on the momentum stocks list (3 companies).

This Diagnostics comparison names 5 specific ways its own evidence can mislead, all listed below. All 9 companies here report on comparable dates, so no rank carries a stale marker. 1 has second-source figures left out because the two sources disagree. A high growth rate can still come from a very small starting figure.

Keep these limits visible

• A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
• A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
• The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
• An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
• 1 company is missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.

This comparison is built from the reported filings of 9 Diagnostics companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 30 October 2026.

1 of 9 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: 3B Blackbio DX Ltd (3BBLACKBIO): its two data sources disagree by up to 41% on reported income across 15 comparable periods, so its derived ratios are withheld.

These 24 answers restate the Diagnostics comparison above in question form. Every one is computed from the same 9 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 30 October 2026. Nothing here is estimated, and none of it is a recommendation.